Ustekinumab is more effective than azathioprine to prevent endoscopic postoperative recurrence in Crohn's disease.
Fiche publication
Date publication
mai 2021
Journal
United European gastroenterology journal
Auteurs
Membres identifiés du Cancéropôle Est :
Dr VUITTON Lucine, Pr PEYRIN-BIROULET Laurent
Tous les auteurs :
Buisson A, Nancey S, Manlay L, Rubin DT, Hebuterne X, Pariente B, Fumery M, Laharie D, Roblin X, Bommelaer G, Pereira B, Peyrin-Biroulet L, Vuitton L,
Lien Pubmed
Résumé
Preventing postoperative recurrence (POR) is a major concern in Crohn's disease (CD). While azathioprine is an option, no data is available on ustekinumab efficacy in this situation.
Mots clés
Crohn's disease, azathioprine, postoperative recurrence, ustekinumab
Référence
United European Gastroenterol J. 2021 May 5;: